2025 Q4 -tulosraportti
74 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 100 | - | - | ||
| 200 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenNovo Nordisk: First major obstacle overcome – here we see the next price target https://ugebrev.dk/flashnews/novo-nordisk-foerste-store-forhindringer-her-ser-vi-naeste-kursmaal/
·2 t sittenThe price will be somewhere in the 300s this summer. What will be exciting is how much? - Wegovy HD has almost neutralized Eli's competitive advantage Zepbound. At the same time, Semaglutide is preferred by the majority among doctors - The Wegovy pill is breaking all records currently and looks set to be the clear winner in the pill market. Foundayo had a weak start with 1300 in the first 2 days - Foundayo has gotten a damaged reputation regarding potential liver damage At the same time, a picture is now emerging that Semaglutide, which has documented cardiovascular benefits, is a safer molecule - against Eli's chemical molecule which possibly has none or, in the worst case, downsides The uncertainty around Foundayo is possibly starting to spread to Eli's entire portfolio...
·3 t sitten · MuokattuIG trader weekend. trade. When Wall Street is down around 0.64 percent and Germany 40 around 0.86 percent, STOXX 600 will often open weaker tomorrow with a decline perhaps of 0.3 percent to O,8 percent, depending on what happened in Asia, on interest rates ,oil and the news flow.
·2 t sittenThe capital market reacts less and less to Trump's outbursts. Last weekend, the oil price, WTI, rose to 105$ on Monday. The news was that the USA and Iran had not reached an agreement. And tomorrow the oil price will be around 90$ and everything immediately looks much worse. The market simply no longer believes in Trump's theatrics. And neither do the Iranians. I don't think the shares will fall particularly much tomorrow. Nasdaq has become immune to the Middle East. We'll see if I'm right.
·16 t sittenI wrote this post the other day. "It's really pushing in the USA to move the price upwards just like yesterday and is currently 2 kr above the Danish listing." For some days there in the USA, it had indicated that it would go up, where the Danish listing only moved a little. Quickly a comment comes, about why one cares about 2 kr - it's a waste of time. In half a year, I don't care if it rises 2 kr from e.g. 200 to 202, but after this long downturn from approx 1.000 kr (I was only in from 541), I think one is looking for the answer to whether 230-240 kr was the bottom (We'll find that out 6/5). If that's it, then I also believe that it will be heavily bought up. And I also believe that's why the Friday news about prescription sales is being followed so closely. One hopes that the bleeding has stopped. Many are sitting with a large ÷ and hoping for a rise, others have shorted and are hoping for a fall. Regardless of which boat one is in, I think it's a shame that some feel the need to trash others. Come with some links and arguments for the claim and let's discuss and become wiser....it might well be that the other group is right. Otherwise refrain from commenting 🙂
·19 t sittenNovo Nordisk will have a huge advantage after FDA has demanded new information from Eli Lilly after it has emerged that there is suspicion of liver damage. It can take Eli Lilly not months but years to document that there is no connection or is there !! Doctors will be reluctant to prescribe Eli Lilly prescriptions and that will benefit Novo not only for months but for years. Who dares to take Eli Lilly's pill or generic medicine.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
74 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenNovo Nordisk: First major obstacle overcome – here we see the next price target https://ugebrev.dk/flashnews/novo-nordisk-foerste-store-forhindringer-her-ser-vi-naeste-kursmaal/·2 t sittenThe price will be somewhere in the 300s this summer. What will be exciting is how much? - Wegovy HD has almost neutralized Eli's competitive advantage Zepbound. At the same time, Semaglutide is preferred by the majority among doctors - The Wegovy pill is breaking all records currently and looks set to be the clear winner in the pill market. Foundayo had a weak start with 1300 in the first 2 days - Foundayo has gotten a damaged reputation regarding potential liver damage At the same time, a picture is now emerging that Semaglutide, which has documented cardiovascular benefits, is a safer molecule - against Eli's chemical molecule which possibly has none or, in the worst case, downsides The uncertainty around Foundayo is possibly starting to spread to Eli's entire portfolio...
- ·3 t sitten · MuokattuIG trader weekend. trade. When Wall Street is down around 0.64 percent and Germany 40 around 0.86 percent, STOXX 600 will often open weaker tomorrow with a decline perhaps of 0.3 percent to O,8 percent, depending on what happened in Asia, on interest rates ,oil and the news flow.·2 t sittenThe capital market reacts less and less to Trump's outbursts. Last weekend, the oil price, WTI, rose to 105$ on Monday. The news was that the USA and Iran had not reached an agreement. And tomorrow the oil price will be around 90$ and everything immediately looks much worse. The market simply no longer believes in Trump's theatrics. And neither do the Iranians. I don't think the shares will fall particularly much tomorrow. Nasdaq has become immune to the Middle East. We'll see if I'm right.
- ·16 t sittenI wrote this post the other day. "It's really pushing in the USA to move the price upwards just like yesterday and is currently 2 kr above the Danish listing." For some days there in the USA, it had indicated that it would go up, where the Danish listing only moved a little. Quickly a comment comes, about why one cares about 2 kr - it's a waste of time. In half a year, I don't care if it rises 2 kr from e.g. 200 to 202, but after this long downturn from approx 1.000 kr (I was only in from 541), I think one is looking for the answer to whether 230-240 kr was the bottom (We'll find that out 6/5). If that's it, then I also believe that it will be heavily bought up. And I also believe that's why the Friday news about prescription sales is being followed so closely. One hopes that the bleeding has stopped. Many are sitting with a large ÷ and hoping for a rise, others have shorted and are hoping for a fall. Regardless of which boat one is in, I think it's a shame that some feel the need to trash others. Come with some links and arguments for the claim and let's discuss and become wiser....it might well be that the other group is right. Otherwise refrain from commenting 🙂
- ·19 t sittenNovo Nordisk will have a huge advantage after FDA has demanded new information from Eli Lilly after it has emerged that there is suspicion of liver damage. It can take Eli Lilly not months but years to document that there is no connection or is there !! Doctors will be reluctant to prescribe Eli Lilly prescriptions and that will benefit Novo not only for months but for years. Who dares to take Eli Lilly's pill or generic medicine.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 100 | - | - | ||
| 200 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
74 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenNovo Nordisk: First major obstacle overcome – here we see the next price target https://ugebrev.dk/flashnews/novo-nordisk-foerste-store-forhindringer-her-ser-vi-naeste-kursmaal/·2 t sittenThe price will be somewhere in the 300s this summer. What will be exciting is how much? - Wegovy HD has almost neutralized Eli's competitive advantage Zepbound. At the same time, Semaglutide is preferred by the majority among doctors - The Wegovy pill is breaking all records currently and looks set to be the clear winner in the pill market. Foundayo had a weak start with 1300 in the first 2 days - Foundayo has gotten a damaged reputation regarding potential liver damage At the same time, a picture is now emerging that Semaglutide, which has documented cardiovascular benefits, is a safer molecule - against Eli's chemical molecule which possibly has none or, in the worst case, downsides The uncertainty around Foundayo is possibly starting to spread to Eli's entire portfolio...
- ·3 t sitten · MuokattuIG trader weekend. trade. When Wall Street is down around 0.64 percent and Germany 40 around 0.86 percent, STOXX 600 will often open weaker tomorrow with a decline perhaps of 0.3 percent to O,8 percent, depending on what happened in Asia, on interest rates ,oil and the news flow.·2 t sittenThe capital market reacts less and less to Trump's outbursts. Last weekend, the oil price, WTI, rose to 105$ on Monday. The news was that the USA and Iran had not reached an agreement. And tomorrow the oil price will be around 90$ and everything immediately looks much worse. The market simply no longer believes in Trump's theatrics. And neither do the Iranians. I don't think the shares will fall particularly much tomorrow. Nasdaq has become immune to the Middle East. We'll see if I'm right.
- ·16 t sittenI wrote this post the other day. "It's really pushing in the USA to move the price upwards just like yesterday and is currently 2 kr above the Danish listing." For some days there in the USA, it had indicated that it would go up, where the Danish listing only moved a little. Quickly a comment comes, about why one cares about 2 kr - it's a waste of time. In half a year, I don't care if it rises 2 kr from e.g. 200 to 202, but after this long downturn from approx 1.000 kr (I was only in from 541), I think one is looking for the answer to whether 230-240 kr was the bottom (We'll find that out 6/5). If that's it, then I also believe that it will be heavily bought up. And I also believe that's why the Friday news about prescription sales is being followed so closely. One hopes that the bleeding has stopped. Many are sitting with a large ÷ and hoping for a rise, others have shorted and are hoping for a fall. Regardless of which boat one is in, I think it's a shame that some feel the need to trash others. Come with some links and arguments for the claim and let's discuss and become wiser....it might well be that the other group is right. Otherwise refrain from commenting 🙂
- ·19 t sittenNovo Nordisk will have a huge advantage after FDA has demanded new information from Eli Lilly after it has emerged that there is suspicion of liver damage. It can take Eli Lilly not months but years to document that there is no connection or is there !! Doctors will be reluctant to prescribe Eli Lilly prescriptions and that will benefit Novo not only for months but for years. Who dares to take Eli Lilly's pill or generic medicine.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 100 | - | - | ||
| 200 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt